PharmGen Science, Inc.
Financials
Valuation Metrics
PharmGen Science, Inc.'s Market Cap is ₩753B. At end of 2025 it was ₩941B. Ranked #1437 of 2,436 in KR market (top 59%), #622 of 787 on KOSPI (top 79%), #158 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 68%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 75.33B KRW | KR#1,437/2,436 Sec#158/234 |
| Revenue | 173.52B KRW | KR#1,089/2,436 Sec#65/234 |
| Net Income | -116.92B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 199.06B KRW | KR#1,284/2,436 Sec#96/234 |
| Net Assets | 150.36B KRW | KR#1,103/2,436 Sec#80/234 |
| Employees | 254 | KR#911/2,436 Sec#79/234 |
| Value | ||
| P/B | 0.50x | KR#803/2,436 Sec#35/234 |
| P/S | 0.43x | KR#824/2,436 Sec#25/234 |
| EV/EBITDA | 10.93x | KR#652/2,436 Sec#31/234 |
| FCF Yield | 5.12% | KR#859/2,436 Sec#42/234 |
| Profitability | ||
| ROE | -77.76% | KR#2,321/2,436 Sec#213/234 |
| ROA | -58.74% | KR#2,363/2,436 Sec#220/234 |
| Op. Margin | 3.29% | KR#1,159/2,436 Sec#91/234 |
| Revenue Growth | 1.04% | KR#1,373/2,436 Sec#128/234 |
| Earnings Growth | -3248.14% | KR#1,737/2,436 Sec#121/234 |
| Financial Health | ||
| Debt Ratio | 32.38% | KR#106/2,436 Sec#14/234 |
| Total Debt | 5.50B KRW | KR#1,770/2,436 Sec#169/234 |
| FCF | 3.86B KRW | KR#964/2,436 Sec#68/234 |
| Cash | 18.41B KRW | KR#1,291/2,436 Sec#97/234 |
| Current Ratio | 2.90x | KR#640/2,436 Sec#86/234 |
| Net Debt/EBITDA | -2.26x | KR#274/2,436 Sec#15/234 |
| Performance | ||
| 1Y Return | -25.86% | KR#1,467/2,436 Sec#126/234 |
| 1M Return | 4.23% | KR#530/2,436 Sec#46/234 |
| From 52W High | -39.44% | KR#732/2,436 Sec#52/234 |
| 1Y MDD | -44.97% | KR#701/2,436 Sec#57/234 |
| Trading | ||
| Volume | 26,995 shares | KR#1,716/2,436 Sec#172/234 |
| Foreign Own. | 2.63% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -5,961 KRW | KR—/2,436 Sec—/234 |
| BPS | 6,862 KRW | KR#1,202/2,436 Sec#86/234 |
Company Info
Established in 1966 as Sudo Pharmaceutical Industry, this company engages in digestive system therapeutics and health functional foods. With headquarters and production facilities in Hwaseong, Gyeonggi-do, it operates wholesale and national branches, a global R&D center, and a development division, focusing on selling professional and general pharmaceuticals and new drug development. In 2021, it established a biosimilar new drug division and recruited experts, and in 2022, announced its R&D Vision 2030, aiming to become a specialized company in digestive system new drug development.